Advancing Antiparasitic Drug Development in Minor Ruminant Species - PROJECT SUMMARY/ABSTRACT Project Title: Advancing Antiparasitic Drug Development in Minor Ruminant Species FDA CVM has identified a critical need for new antiparasitic drugs in sheep and goats, food-producing minor species for which approved treatment options are severely limited. Haemonchus contortus and other gastrointestinal nematodes cause severe morbidity and mortality in sheep and goats, and resistance against approved antiparasitic drugs continues to worsen. Only one antiparasitic drug is currently approved for bison. The limited financial return on minor species drug development has prevented industry from generating the species-specific efficacy, pharmacokinetic, safety, and residue depletion data required for NADA approval. This Cooperative Agreement will directly address this market failure by generating the regulatory science data needed to support antiparasitic drug approvals in sheep, goats, and bison under the Minor Use and Minor Species (MUMS) Animal Health Act. The long-term goal of this program is to improve the availability and effectiveness of antiparasitic therapeutics for food-producing minor species, directly addressing the FY2026 FDA CVM AVIC priority areas of high-priority animal drugs for minor ruminant species and human food safety regulatory science. The specific objective of this Cooperative Agreement is to develop a translational regulatory science platform and generate species-specific data advancing antiparasitic drug approvals in minor ruminants through three aims, leveraging complementary expertise across a multidisciplinary, multi-institution team. Aim 1 will establish a comparative ruminant in vitro pharmacology platform encompassing absolute quantitation of cytochrome P450 (CYP) enzymes and accessory proteins in liver microsomes, recombinant CYP panel development, reaction phenotyping and metabolic stability of antiparasitic candidates, and efflux transporter characterization across cattle, sheep, goats, and bison. This platform will generate mechanistic data to explain interspecies differences in drug disposition, support candidate prioritization, and inform future physiologically based pharmacokinetic modeling. In Aim 2, priority antiparasitic candidates will be advanced to controlled and field efficacy and pharmacokinetic studies in sheep, goats, and bison, with target animal safety studies conducted in sheep and goats, generating the evidentiary data package required for NADA submission. Aim 3 will generate tissue and milk residue depletion data in sheep and goats and tissue residue depletion data in bison for priority candidates, supporting human food safety assessment and withdrawal time determination. Aim 3 will also evaluate repeated tissue biopsy sampling as a minimally invasive alternative to terminal tissue collection, which if validated would reduce animal burden and cost of withdrawal time determination for minor species. This project will generate efficacy, safety, and residue depletion data supporting NADA submissions for priority antiparasitic candidates in sheep, goats, and bison, while establishing the comparative ruminant CYP/transporter platform and biopsy-based residue approach as regulatory science tools applicable to future drug classes.